Webster Brian Daniel sold $443K of KMTS

Webster Brian Daniel (See Remarks) sold 15,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $29.56 ($29.52–$29.89, $0.44M total) across 2 trades on 2026-10-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Webster Brian Daniel
Published Oct 22, 2026, 8:24 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Bearish
medium confidence
Mentioned
$KMTS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSBearishLow
01

Why it matters

The disclosed sale is the first public report of this transaction, providing new information for traders.

02

Market read

A modest insider sale in a micro‑cap; may cause short‑term price pressure but limited broader market relevance.

03

What to watch

The insider retains a large stake (445,215 shares) indicating continued confidence.

Relevance 3/10Novelty 3/10Timing: post‑market filing today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources for insider activity.

Company-level read

Ticker impact

$KMTSBearishMedium confidence
Context

Officer/director sold 15,000 shares for $443K via a 10b5‑1 plan on 2026‑10‑20.

Expected impact

likely slight downward pressure as the market prices the insider sell.

Evidence & confidence

A $443K sale by an officer is material for a micro‑cap, but the amount is modest relative to float.

Market effects

Minimal impact on the broader medical device sector.

No significant regional effect.

Limited to investors tracking insider activity in small caps.

Counterpoint

The sale could be routine under a pre‑arranged plan and not indicate negative fundamentals.

Key entities

  • Kestral Medical Technologies, Ltd.

    Medical device manufacturer listed on Nasdaq under KMTS.

  • Webster Brian Daniel

    Officer and director of KMTS who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.